From: The association between liver enzymes and risk of type 2 diabetes: the Namwon study
 | Q1 | Q2 | Q3 | Q4 | P for trend |
---|---|---|---|---|---|
AST (units/l) | ≤20 | 21 to 24 | 25 to 30 | ≥31 |  |
Cases/persons at risk | 49/620 | 56/656 | 64/687 | 66/640 | Â |
Model 1 | 1 | 1.09 (0.73-1.62) | 1.20 (0.81-1.77) | 1.34 (0.91-1.98) | 0.116 |
Model 2 | 1 | 1.11 (0.74-1.66) | 1.10 (0.74-1.65) | 1.21 (0.80-1.83) | 0.390 |
Model 3 | 1 | 1.12 (0.73-1.71) | 1.09 (0.72-1.65) | 1.15 (0.76-1.76) | 0.565 |
Model 4 | 1 | 0.98 (0.63-1.52) | 0.93 (0.61-1.43) | 1.07 (0.69-1.66) | 0.794 |
ALT (units/l) | ≤15 | 16 to 20 | 21 to 29 | ≥30 |  |
Cases/persons at risk | 31/615 | 46/632 | 81/710 | 77/646 | Â |
Model 1 | 1 | 1.49 (0.93-2.39) | 2.49 (1.62-3.83) | 2.67 (1.72-4.15) | <0.001 |
Model 2 | 1 | 1.42 (0.89-2.28) | 2.19 (1.41-3.41) | 2.11 (1.33-3.35) | <0.001 |
Model 3 | 1 | 1.53 (0.93-2.52) | 2.24 (1.40-3.59) | 2.31 (1.42-3.75) | <0.001 |
Model 4 | 1 | 1.36 (0.82-2.27) | 2.03 (1.26-3.29) | 1.95 (1.18-3.21) | 0.004 |
GGT (units/l) | ≤19 | 20 to 30 | 31 to 54 | ≥55 |  |
Cases/persons at risk | 38/661 | 44/651 | 72/635 | 81/656 | Â |
Model 1 | 1 | 1.20 (0.77-1.89) | 2.14 (1.42-3.23) | 2.38 (1.59-3.57) | <0.001 |
Model 2 | 1 | 1.09 (0.69-1.73) | 2.00 (1.28-3.12) | 2.13 (1.33-3.41) | <0.001 |
Model 3 | 1 | 1.00 (0.62-1.63) | 1.86 (1.17-2.96) | 1.97 (1.21-3.22) | 0.001 |
Model 4 | 1 | 0.86 (0.52-1.42) | 1.57 (0.97-2.54) | 1.58 (0.95-2.63) | 0.011 |